Research

Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.

This perspective in the American Journal of Kidney Diseases examines how the “Advancing American Kidney Health” Executive Order (AAKH) might reshape the US dialysis market.

In low- and middle-income countries, supplemental income for the elderly may be an effective strategy to improve cognitive function by increasing food security and health care utilization.

Two years after launch, biosimilars for rheumatoid arthritis and other lifelong conditions captured little market share.

There is a significant burden of disease among individuals with CHD; the disease affects quality of life, disability, life expectancy, medical spending, chronic disease, as well as employment and education outcomes.

The COVID-19 pandemic has imposed significant and far-reaching health and economic costs. This white paper models and monetizes the health-related benefits of two hypothetical treatments administered either before or after hospitalization; both generate substantial value.

Christen Linke Young explains the dangers of junk insurance.

A review of 145 opioid policy evaluation studies found that greater adoption of more rigorous study designs and statistical methods is warranted.

This study provides the first comparison of trends in dementia prevalence in the U.S. population using 3 different dementia ascertainments/data sources. They found there are still substantial differences across measures in dementia prevalence among Blacks and Hispanics.

Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.